Compare NEWT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEWT | FHTX |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.6M | 419.9M |
| IPO Year | 2013 | 2020 |
| Metric | NEWT | FHTX |
|---|---|---|
| Price | $12.32 | $6.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $15.33 | $11.50 |
| AVG Volume (30 Days) | 241.5K | ★ 299.4K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.00% | N/A |
| EPS Growth | 11.22 | ★ 25.32 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | $12.45 | $20.13 |
| P/E Ratio | $13.70 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $9.59 | $3.27 |
| 52 Week High | $15.69 | $7.61 |
| Indicator | NEWT | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.57 | 51.05 |
| Support Level | $11.41 | $4.21 |
| Resistance Level | $12.38 | $6.76 |
| Average True Range (ATR) | 0.32 | 0.53 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 8.19 | 12.95 |
NewtekOne Inc provides business and financial solutions under the Newtek and NewtekOne brands to the independent business owner (SMB) market. Its services are offered online and in some cases delivered by staff via video and voice calls. The company offers lending products, FDIC insured deposit products and services, payments processing, payroll services and insurance brokerage services. Loan products include SBA 7(a), ALP, SBA 504, and traditional C&I and CRE bank loans, while deposit products include consumer high yield savings accounts, high yield certificates of deposit, zero-fee business checking and business money market accounts. The company operates through four reportable segments Banking, Alternative Lending, NSBF and Payments.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.